

Supplemental Table 1: Least square mean (nM oxy / mM PL) and [95% CI] with treatment effects [95% CI] (adjusted for age and sex).

Lipo	Chemistry	Parent		Baseline	Final	Difference (% change baseline)	pVal
		FA	Regioisomer				
HDL	Alc	LA	9-HODE	460 (350, 610)	530 (400, 690)	14 (-5, 37)	0.15
HDL	Alc	LA	13-HODE	2020 (1530, 2660)	2320 (1760, 3060)	.	.
LDL	Alc	LA	9-HODE	590 (440, 790)	540 (400, 730)	-6 (-21, 12)	0.46
LDL	Alc	LA	13-HODE	2790 (2080, 3750)	2660 (1980, 3580)	.	.
VLDL	Alc	LA	9-HODE	570 (380, 870)	630 (420, 950)	9 (-19, 46)	0.57
VLDL	Alc	LA	13-HODE	2690 (1780, 4070)	2890 (1910, 4370)	.	.
Plasma	Alc	LA	9-HODE	380 (300, 470)	440 (350, 550)	15 (2, 29)	0.03
Plasma	Alc	LA	13-HODE	1660 (1330, 2080)	1890 (1510, 2360)	.	.
HDL	Alc	aLA	9-HOTE	4.1 (3.0, 5.7)	5.0 (3.7, 6.9)	14 (-9, 43)	0.26
HDL	Alc	aLA	13-HOTE	6.1 (4.5, 8.4)	6.5 (4.8, 9.0)	.	.
LDL	Alc	aLA	9-HOTE	5.0 (3.6, 7.1)	5.5 (3.9, 7.8)	4 (-15, 27)	0.72
LDL	Alc	aLA	13-HOTE	4.3 (3.1, 6.1)	4.2 (3.0, 5.9)	.	.
VLDL	Alc	aLA	9-HOTE	18.6 (11.7, 29.5)	22.0 (13.9, 35.0)	15 (-20, 66)	0.43
VLDL	Alc	aLA	13-HOTE	17.2 (10.8, 27.2)	19.2 (12.1, 30.5)	.	.
Plasma	Alc	aLA	9-HOTE	7.8 (5.7, 10.6)	9.1 (6.7, 12.4)	15 (-7, 42)	0.18
Plasma	Alc	aLA	13-HOTE	10.4 (7.6, 14.2)	11.9 (8.7, 16.2)	.	.
HDL	Alc	dgLA	15(S)-HETrE	38 (30, 49)	35 (27, 44)	-10 (-31, 18)	0.41
LDL	Alc	dgLA	15(S)-HETrE	26 (18, 39)	20 (14, 30)	-22 (-47, 16)	0.2
VLDL	Alc	dgLA	15(S)-HETrE	24 (16, 36)	18 (12, 27)	-25 (-59, 36)	0.32
Plasma	Alc	dgLA	15(S)-HETrE	26 (19, 35)	24 (18, 32)	-8 (-34, 29)	0.62
HDL	Alc	AA	5-HETE	208 (162, 267)	172 (134, 220)	-15 (-24, -4)	0.01
HDL	Alc	AA	9-HETE	168 (131, 216)	155 (121, 199)	.	.
HDL	Alc	AA	12-HETE	165 (129, 212)	135 (105, 173)	.	.
HDL	Alc	AA	15-HETE	554 (432, 711)	478 (373, 613)	.	.
LDL	Alc	AA	5-HETE	162 (125, 211)	119 (92, 155)	-29 (-36, -21)	<0.0001
LDL	Alc	AA	9-HETE	137 (105, 177)	104 (80, 135)	.	.
LDL	Alc	AA	12-HETE	104 (80, 134)	74 (57, 96)	.	.
LDL	Alc	AA	15-HETE	327 (252, 424)	211 (163, 274)	.	.
VLDL	Alc	AA	5-HETE	112 (72, 175)	88 (56, 138)	-18 (-32, 0)	0.05
VLDL	Alc	AA	9-HETE	81 (52, 127)	69 (44, 107)	.	.
VLDL	Alc	AA	12-HETE	54 (34, 84)	43 (28, 67)	.	.
VLDL	Alc	AA	15-HETE	162 (104, 254)	138 (88, 215)	.	.
Plasma	Alc	AA	5-HETE	121 (90, 163)	120 (89, 162)	-4 (-17, 10)	0.55
Plasma	Alc	AA	9-HETE	56 (41, 75)	54 (40, 73)	.	.
Plasma	Alc	AA	12-HETE	62 (46, 83)	55 (41, 74)	.	.
Plasma	Alc	AA	15-HETE	310 (231, 417)	304 (226, 410)	.	.
HDL	Alc	EPA	5-HEPE	14.7 (10.6, 20.3)	53.1 (38.4, 73.4)	294 (212, 397)	<0.0001
HDL	Alc	EPA	12-HEPE	10.3 (7.4, 14.2)	42.9 (31.1, 59.3)	.	.
HDL	Alc	EPA	15-HEPE	3.6 (2.6, 5)	14.6 (10.5, 20.1)	.	.
LDL	Alc	EPA	5-HEPE	10.9 (7.8, 15.2)	42.2 (30.2, 58.9)	303 (232, 391)^a	<0.0001

LDL	Alc	EPA	12-HEPE	7 (5, 9.8)	28.4 (20.4, 39.7)	.	.
LDL	Alc	EPA	15-HEPE	2.3 (1.7, 3.3)	9.9 (7.1, 13.8)	.	.
VLDL	Alc	EPA	5-HEPE	10.2 (6, 17.2)	47 (27.8, 79.6)	352 (228, 522)^a	<0.0001
VLDL	Alc	EPA	12-HEPE	5.5 (3.2, 9.2)	23.4 (13.9, 39.6)	.	.
VLDL	Alc	EPA	15-HEPE	1.8 (1.1, 3.1)	8.6 (5.1, 14.5)	.	.
Plasma	Alc	EPA	5-HEPE	12.6 (8.9, 17.9)	61.7 (43.5, 87.5)	400 (313, 505)	<0.0001
Plasma	Alc	EPA	12-HEPE	6.5 (4.6, 9.2)	30.6 (21.6, 43.4)	.	.
Plasma	Alc	EPA	15-HEPE	2.2 (1.6, 3.2)	12.1 (8.6, 17.2)	.	.
HDL	Alc	DHA	17-HDoHE	134 (101, 178)	276 (208, 367)	106 (23, 244)	0.009
LDL	Alc	DHA	17-HDoHE	48 (35, 67)	85 (61, 117)	75 (24, 149)	0.004
VLDL	Alc	DHA	17-HDoHE	42 (26, 67)	135 (84, 215)	220 (57, 552)^a	0.003
Plasma	Alc	DHA	17-HDoHE	71 (50, 102)	183 (128, 264)	157 (71, 287)	0.0002
HDL	Ket	LA	9-KODE	109 (91, 131)	109 (91, 131)	0 (-15, 17)	0.97
LDL	Ket	LA	9-KODE	191 (153, 238)	181 (145, 226)	-5 (-24, 18)	0.61
VLDL	Ket	LA	9-KODE	284 (197, 408)	319 (221, 459)	12 (-32, 85)	0.63
Plasma	Ket	LA	9-KODE	89 (64, 124)	100 (71, 139)	12 (-13, 44)	0.35
HDL	Ket	AA	5-KETE	38 (27, 53)	28 (20, 39)	-32 (-45, -17)	0.0004
HDL	Ket	AA	15-KETE	92 (66, 128)	57 (41, 79)	.	.
LDL	Ket	AA	5-KETE	44 (33, 58)	32 (24, 43)	-32 (-42, -20)	<0.0001
LDL	Ket	AA	15-KETE	132 (99, 175)	82 (62, 110)	.	.
VLDL	Ket	AA	5-KETE	45 (27, 75)	38 (23, 63)	-20 (-44, 16)	0.23
VLDL	Ket	AA	15-KETE	245 (148, 407)	188 (114, 313)	.	.
Plasma	Ket	AA	5-KETE	52 (36, 74)	47 (33, 68)	-10 (-30, 15)	0.39
Plasma	Ket	AA	15-KETE	266 (185, 381)	234 (163, 336)	.	.
HDL	Leuko	AA	6-trans-LTB4
LDL	Leuko	AA	6-trans-LTB4	0.15 (0.10, 0.20)	0.12 (0.09, 0.17)	-14 (-47, 39)	0.50
VLDL	Leuko	AA	6-trans-LTB4	0.078 (0.045, 0.134)	0.073 (0.043, 0.127)	-6 (-57, 106)	0.88
Plasma	Leuko	AA	6-trans-LTB4	0.078 (0.057, 0.109)	0.075 (0.054, 0.104)	-4 (-33, 37)	0.8
HDL	Epox	LA	9(10)-EpOME	273 (210, 355)	273 (210, 354)	1 (-13, 19)	0.86
HDL	Epox	LA	12(13)-EpOME	328 (253, 426)	338 (260, 438)	.	.
LDL	Epox	LA	9(10)-EpOME	237 (188, 300)	236 (187, 299)	-2 (-13, 11)	0.78
LDL	Epox	LA	12(13)-EpOME	300 (237, 379)	291 (230, 367)	.	.
VLDL	Epox	LA	9(10)-EpOME	269 (194, 374)	277 (199, 385)	5 (-19, 35)	0.71
VLDL	Epox	LA	12(13)-EpOME	324 (233, 451)	347 (250, 482)	.	.
Plasma	Epox	LA	9(10)-EpOME	134 (99, 181)	152 (112, 205)	9 (-10, 33)	0.38
Plasma	Epox	LA	12(13)-EpOME	157 (116, 212)	165 (122, 223)	.	.
HDL	Epox	aLA	9(10)-EpODE	19.4 (12.3, 30.6)	20.5 (13, 32.4)	7 (-18, 40)	0.62
HDL	Epox	aLA	12(13)-EpODE	4.1 (2.6, 6.4)	4.6 (2.9, 7.3)	.	.
HDL	Epox	aLA	15(16)-EpODE	17.6 (11.2, 27.8)	18.1 (11.5, 28.5)	.	.
LDL	Epox	aLA	9(10)-EpODE	15.2 (12.3, 18.7)	14.4 (11.6, 17.8)	-4 (-17, 12)	0.62
LDL	Epox	aLA	12(13)-EpODE	2.1 (1.7, 2.5)	2.1 (1.7, 2.6)	.	.
LDL	Epox	aLA	15(16)-EpODE	16 (12.9, 19.7)	14.8 (11.9, 18.3)	.	.
VLDL	Epox	aLA	9(10)-EpODE	48 (32.5, 70.8)	56.4 (38.2, 83.2)	21 (-4, 51)	0.10
VLDL	Epox	aLA	12(13)-EpODE	6.4 (4.3, 9.4)	8.2 (5.5, 12.1)	.	.

VLDL	Epox	aLA	15(16)-EpODE	50.2 (34, 74.1)	58.4 (39.6, 86.2)	.	.
Plasma	Epox	aLA	9(10)-EpODE	28.2 (20.5, 38.7)	31.5 (22.9, 43.3)	11 (-5, 30)	0.17
Plasma	Epox	aLA	12(13)-EpODE	2.5 (1.8, 3.5)	2.9 (2.1, 4.0)	.	.
Plasma	Epox	aLA	15(16)-EpODE	29.4 (21.4, 40.4)	31.5 (22.9, 43.3)	.	.
HDL	Epox	AA	8(9)-EpETrE	106 (75, 150)	77 (54, 109)	-23 (-33, -12)	0.0004
HDL	Epox	AA	11(12)-EpETrE	262 (185, 372)	207 (146, 293)	.	.
HDL	Epox	AA	14(15)-EpETrE	208 (147, 295)	165 (116, 234)	.	.
LDL	Epox	AA	8(9)-EpETrE	55 (41, 74)	39 (29, 53)	-27 (-35, -19)	<0.0001
LDL	Epox	AA	11(12)-EpETrE	131 (97, 175)	101 (75, 135)	.	.
LDL	Epox	AA	14(15)-EpETrE	114 (85, 153)	81 (60, 109)	.	.
VLDL	Epox	AA	8(9)-EpETrE	39 (25, 60)	35 (23, 54)	-9 (-24, 9)	0.31
VLDL	Epox	AA	11(12)-EpETrE	88 (57, 137)	79 (51, 122)	.	.
VLDL	Epox	AA	14(15)-EpETrE	73 (47, 113)	69 (44, 106)	.	.
Plasma	Epox	AA	8(9)-EpETrE	39 (28, 54)	34 (25, 48)	-8 (-19, 6)	0.24
Plasma	Epox	AA	11(12)-EpETrE	87 (62, 120)	80 (58, 112)	.	.
Plasma	Epox	AA	14(15)-EpETrE	70 (50, 97)	68 (49, 94)	.	.
HDL	Epox	EPA	14(15)-EpETE	10.5 (6.4, 17.2)	43.2 (26.8, 69.8)	325 (184, 536)	<0.0001
HDL	Epox	EPA	17(18)-EpETE	18.7 (11.7, 29.8)	81.7 (51.3, 130.2)	.	.
LDL	Epox	EPA	14(15)-EpETE	5.1 (3.5, 7.5)	22.7 (15.5, 33.4)	318 (224, 439)	<0.0001
LDL	Epox	EPA	17(18)-EpETE	10.4 (7.1, 15.3)	41.1 (28, 60.3)	.	.
VLDL	Epox	EPA	14(15)-EpETE	5.0 (3.0, 8.5)	22.7 (13.4, 38.3)	379 (236, 584)	<0.0001
VLDL	Epox	EPA	17(18)-EpETE	6.4 (3.8, 10.8)	32.5 (19.2, 54.8)	.	.
Plasma	Epox	EPA	14(15)-EpETE	2.4 (1.6, 3.6)	13.6 (8.9, 20.8)	436 (307, 606)	<0.0001
Plasma	Epox	EPA	17(18)-EpETE	6.0 (3.9, 9.1)	29.8 (19.5, 45.5)	.	.
HDL	Epox	DHA	16(17)-EpDPE	43 (27, 67)	77 (49, 121)	81 (7, 206)	0.03
LDL	Epox	DHA	16(17)-EpDPE	18 (12, 26)	29 (19, 43)	63 (-8, 188)	0.09
VLDL	Epox	DHA	16(17)-EpDPE	14 (8, 24)	56 (33, 95)	304 (107, 690)	0.0005
Plasma	Epox	DHA	16(17)-EpDPE	16 (11, 25)	46 (30, 70)	182 (73, 358)	0.004
HDL	Diol	LA	9,10-DiHOME	46 (36, 59)	45 (35, 59)	2 (-18, 27)	0.86
HDL	Diol	LA	12,13-DiHOME	8.5 (6.6, 11)	8.9 (6.9, 11.4)	.	.
LDL	Diol	LA	9,10-DiHOME	20 (16, 25)	18 (14, 22)	-4 (-18, 13)	0.63
LDL	Diol	LA	12,13-DiHOME	3.4 (2.8, 4.3)	3.6 (2.9, 4.4)	.	.
VLDL	Diol	LA	9,10-DiHOME	16 (11, 24)	17 (11, 25)	21 (-13, 67)	0.25
VLDL	Diol	LA	12,13-DiHOME	2.3 (1.6, 3.5)	3.2 (2.1, 4.9)	.	.
Plasma	Diol	LA	9,10-DiHOME	21 (17, 28)	24 (19, 31)	24 (1, 52)	0.04
Plasma	Diol	LA	12,13-DiHOME	1.6 (1.3, 2.1)	2.3 (1.8, 2.9)	.	.
HDL	Diol	aLA	9,10-DiHODE
LDL	Diol	aLA	9,10-DiHODE
VLDL	Diol	aLA	9,10-DiHODE	0.07 (0.04, 0.14)	0.09 (0.04, 0.17)	19 (-54, 207)	0.7
Plasma	Diol	aLA	9,10-DiHODE	0.08 (0.06, 0.13)	0.10 (0.07, 0.16)	22 (-27, 105)	0.41
HDL	Diol	AA	5,6-DiHETrE	3.54 (2.88, 4.36)	2.63 (2.14, 3.23)	-22 (-31, -13)	<0.0001
HDL	Diol	AA	8,9-DiHETrE	1.89 (1.54, 2.33)	1.38 (1.12, 1.69)	.	.
HDL	Diol	AA	11,12-DiHETrE	0.60 (0.49, 0.74)	0.44 (0.36, 0.55)	.	.
HDL	Diol	AA	14,15-DiHETrE	0.50 (0.40, 0.61)	0.45 (0.37, 0.55)	.	.

LDL	Diol	AA	5,6-DiHETrE	4.31 (3.47, 5.36)	3.09 (2.49, 3.84)	-28 (-34, -21)	<0.0001
LDL	Diol	AA	8,9-DiHETrE	1.62 (1.30, 2.01)	1.12 (0.90, 1.39)	.	.
LDL	Diol	AA	11,12-DiHETrE	0.55 (0.44, 0.68)	0.38 (0.30, 0.47)	.	.
LDL	Diol	AA	14,15-DiHETrE	0.38 (0.31, 0.48)	0.30 (0.24, 0.38)	.	.
VLDL	Diol	AA	5,6-DiHETrE	2.66 (1.67, 4.22)	2.20 (1.39, 3.49)	-19 (-34, -2)	0.03
VLDL	Diol	AA	8,9-DiHETrE	1.10 (0.69, 1.74)	0.79 (0.50, 1.26)	.	.
VLDL	Diol	AA	11,12-DiHETrE	0.37 (0.23, 0.58)	0.28 (0.18, 0.45)	.	.
VLDL	Diol	AA	14,15-DiHETrE	0.27 (0.17, 0.43)	0.24 (0.15, 0.39)	.	.
Plasma	Diol	AA	5,6-DiHETrE	2.93 (2.33, 3.68)	2.51 (2.00, 3.15)	-7 (-15, 2)	0.12
Plasma	Diol	AA	8,9-DiHETrE	1.17 (0.93, 1.47)	1.10 (0.88, 1.39)	.	.
Plasma	Diol	AA	11,12-DiHETrE	0.37 (0.29, 0.46)	0.32 (0.26, 0.41)	.	.
Plasma	Diol	AA	14,15-DiHETrE	0.24 (0.19, 0.31)	0.25 (0.20, 0.32)	.	.
HDL	Diol	EPA	14,15-DiHETE	1.01 (0.69, 1.48)	1.85 (1.33, 2.57)	49 (2, 118)	0.04
HDL	Diol	EPA	17,18-DiHETE	4.26 (2.99, 6.08)	5.17 (3.64, 7.34)	.	.
LDL	Diol	EPA	14,15-DiHETE	0.41 (0.27, 0.61)	0.83 (0.56, 1.24)	97 (46, 166)	<0.0001
LDL	Diol	EPA	17,18-DiHETE	0.60 (0.38, 0.95)	1.13 (0.75, 1.70)	.	.
VLDL	Diol	EPA	14,15-DiHETE	0.33 (0.22, 0.50)	1.08 (0.71, 1.63)	109 (47, 196)	0.0001
VLDL	Diol	EPA	17,18-DiHETE	0.68 (0.45, 1.05)	0.90 (0.59, 1.36)	.	.
Plasma	Diol	EPA	14,15-DiHETE	0.22 (0.15, 0.32)	0.68 (0.47, 0.98)	158 (99, 235)	<0.0001
Plasma	Diol	EPA	17,18-DiHETE	0.31 (0.21, 0.45)	0.64 (0.44, 0.94)	.	.
HDL	Diol	DHA	19,20-DiHDPA	0.36 (0.24, 0.56)	0.33 (0.21, 0.51)	-9 (-44, 49)	0.70
LDL	Diol	DHA	19,20-DiHDPA	0.06 (0.04, 0.09)	0.12 (0.08, 0.17)	104 (55, 168)	0.0001
VLDL	Diol	DHA	19,20-DiHDPA	0.08 (0.05, 0.13)	0.22 (0.14, 0.37)	180 (44, 443)	0.01
Plasma	Diol	DHA	19,20-DiHDPA	0.06 (0.04, 0.08)	0.16 (0.12, 0.22)	162 (92, 258)	<0.0001
HDL	PG	AA	PGF2a
LDL	PG	AA	PGF2a	0.35 (0.20, 0.60)	0.34 (0.20, 0.58)	-2 (-40, 59)	0.91
VLDL	PG	AA	PGF2a	0.69 (0.44, 1.07)	0.45 (0.28, 0.71)	-35 (-64, 17)	0.14
Plasma	PG	AA	PGF2a	0.84 (0.58, 1.21)	0.59 (0.40, 0.85)	-30 (-53, 4)	0.07
HDL	Triol	LA	9,10-13-TriHOME	5.6 (3.3, 9.5)	5.9 (3.6, 9.6)	19 (-18, 73)	0.34
HDL	Triol	LA	9,12,13-TriHOME	13.6 (8.6, 21.5)	17.8 (11.4, 27.8)	.	.
LDL	Triol	LA	9,10-13-TriHOME	1.5 (0.9, 2.4)	1.7 (1.1, 2.7)	11 (-17, 48)	0.49
LDL	Triol	LA	9,12,13-TriHOME	5.0 (3.1, 8.1)	5.4 (3.4, 8.6)	.	.
VLDL	Triol	LA	9,10-13-TriHOME	1.7 (1.2, 2.5)	1.9 (1.3, 2.8)	8 (-21, 48)	0.62
VLDL	Triol	LA	9,12,13-TriHOME	5.4 (3.7, 7.9)	5.7 (3.9, 8.3)	.	.
Plasma	Triol	LA	9,10-13-TriHOME	1.0 (0.7, 1.5)	1.2 (0.9, 1.8)	16 (-6, 44)	0.17
Plasma	Triol	LA	9,12,13-TriHOME	3.1 (2.2, 4.5)	3.5 (2.5, 5.0)	.	.
HDL	EpKet	LA	EKODE	57 (45, 71)	58 (46, 73)	2 (-21, 31)	0.87
LDL	EpKet	LA	EKODE	92 (72, 117)	86 (68, 110)	-6 (-25, 17)	0.56
VLDL	EpKet	LA	EKODE	126 (88, 183)	139 (96, 201)	10 (-33, 81)	0.69
Plasma	EpKet	LA	EKODE	50 (39, 64)	53 (41, 68)	6 (-19, 39)	0.63

^a The adjustment for age was significant (P<0.05).








Supplemental Table 2: Correlation between oxylipins and erythrocyte content of parent fatty acid.

Oxylipin	Visit	Pearson Correlation				Oxylipin	Pearson Correlation			
		HDL	LDL	VLDL	Plasma		HDL	LDL	VLDL	Plasma
		Mid-chain alcohols				Ketones				
		<i>Arachidonates</i>								
5-HETE	Baseline	0.79				5-KETE				
	Final									
9-HETE	Baseline	0.58								
	Final									
12-HETE	Baseline									
	Final									
15-HETE	Baseline	0.69				15-KETE				
	Final									
		<i>Eicosapentaenoates</i>								
5-HEPE	Baseline		0.67	0.80	0.85					
	Final	0.88	0.58	0.59	0.81					
12-HEPE	Baseline	0.53	0.63	0.72	0.63					
	Final	0.85	0.68	0.72	0.81					
15-HEPE	Baseline	0.64	0.57	0.72	0.74					
	Final	0.82	0.60	0.69	0.77					
		<i>Docosahexaenoates</i>								
17-HDoHE	Baseline		0.60		0.64					
	Final	0.63								
		Epoxides				Vicinal Diols				
		<i>Arachidonates</i>								
8(9)-EpETrE	Baseline					8,9-DiHETrE				
	Final									
11(12)-EpETrE	Baseline					11,12-DiHETrE				
	Final									
14(15)-EpETrE	Baseline					14,15-DiHETrE				
	Final									
		<i>Eicosapentaenoates</i>								
14(15)-EpETE	Baseline	0.63	0.78	0.63	0.56	14,15-DiHETE			0.80	
	Final	0.58	0.70	0.78	0.76		0.65	0.63		0.88
17(18)-EpETE	Baseline	0.58	0.81	0.66	0.70	17,18-DiHETE			0.65	
	Final	0.64	0.71	0.83	0.81				0.69	0.85
		<i>Docosahexaenoates</i>								
16(17)-EpDPE	Baseline		0.81	0.66	0.73	19,20-DiHDPA				0.61

Pearson correlation on $\log(\text{nM oxylipin}) \times \log(\text{erythrocyte parent FA as \%total})$

Where the regression coefficient is significant at $p < 0.05$, it is represented in **bold**; where $p > 0.05$, only color is represented.

Supplemental Table 2; Key

Key	
r	Color
1.00	
0.67	
0.33	
0.00	
-0.33	
-0.67	
-1.00	

Supplemental Table 3: Estimation of changes in epoxide bioactivity with concentrations unmeasured epoxides imputed^a

	<i>Net potency for vasodilation</i>							
	HDL		LDL		VLDL		Plasma	
	<i>Bs</i>	<i>Final</i>	<i>Bs</i>	<i>Final</i>	<i>Bs</i>	<i>Final</i>	<i>Bs</i>	<i>Final</i>
Net AA ^[32]	0.99	0.77	0.52	0.38	0.34	0.31	0.33	0.31
Net EPA ^[32]	0.21	0.85	0.11	0.44	0.09	0.41	0.06	0.28
Net DHA ^[31]	0.21	0.39	0.09	0.15	0.07	0.29	0.08	0.23
Total	1.41	2.02	0.71	0.96	0.50	1.00	0.47	0.82
Fold-change		1.4		1.4		2.0		1.7

^a imputations were made using the reactivity of each double bond implied by Newman and Hammock [33].

^b Net potency measured as $\Sigma -EC_{50} \times [Epoxide]_{measured\ or\ imputed}$ as reported by Ye *et al* & Zhang *et al*.
Note: potencies are measured in nM² / mM PL. Abbreviation: Bs – Baseline.